TIANDE CHEMICAL (00609) released its interim results, with a profit attributable to shareholders of 23.395 million yuan, a decrease of 33.4% year-on-year.
Tiande Chemical (00609) announced its results for the six months ending June 30, 2026, with a revenue of 1.082 billion yuan, an increase of 16.1% year-on-year; the profit attributable to owners of the company was 23.395 million yuan, a decrease of 33.4% year-on-year; basic earnings per share were 0.027 yuan.
TIANDE CHEMICAL (00609) announced its performance for the six months ending June 30, 2026, reporting a revenue of 1.082 billion yuan, a year-on-year increase of 16.1%. The profit attributable to the company's owners was 23.395 million yuan, a year-on-year decrease of 33.4%, with basic earnings per share of 0.027 yuan.
During the review period, the market demand remained weak due to the persistent impact of last years unfavorable macroeconomic environment. Although geopolitical conflicts have led to tight global supply chains, driving up market prices for energy and basic chemical raw materials, the overall selling prices of the group's products still experienced a moderate decrease compared to the same period last year. In response to the weak market conditions, the group adjusted its marketing strategy, focusing on expanding its market presence, broadening its customer base, and continuously increasing the downstream applications of its products. These measures allowed several products to leverage their growth potential, driving an overall increase in the groups sales volume, effectively offsetting the impact of declining product prices on revenue. As a result, the group's revenue achieved the expected growth compared to the same period last year.
Related Articles

PENGO HLDG GP (01865) issued 147 million shares according to the subscription agreement.

ABBISKO-B(02256): It is recommended that the Chinese double foreign name be changed to "Heyu Pharmaceutical Limited Liability Company."

HUAYUEXPRESSWAY (01823) issues profit warning, expecting a mid-term shareholder loss of approximately 34.5 million to 38.1 million yuan.
PENGO HLDG GP (01865) issued 147 million shares according to the subscription agreement.

ABBISKO-B(02256): It is recommended that the Chinese double foreign name be changed to "Heyu Pharmaceutical Limited Liability Company."

HUAYUEXPRESSWAY (01823) issues profit warning, expecting a mid-term shareholder loss of approximately 34.5 million to 38.1 million yuan.

RECOMMEND





